Prior Authorization of Newer Insomnia Medications in Managed Care: Is It Cost Saving?

摘要

Study Objectives:New pharmacotherapeutic treatment options are available to treat patients with 1 or more insomnia symptoms. However, these new Pharmaceuticals are subject to a variety of managed-care tools, such as prior authorizations, that may restrict access to these medications. The objective of this study was to evaluate the economic consequences to a health plan that requires prior authorization for non-benzodiazepine medications approved for the treatment of insomnia characterized by difficulties both falling and staying asleep.